ロード中...
A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors
PURPOSE: BMS-690514 is a novel oral tyrosine kinase inhibitor of ErbB and vascular endothelial growth factor receptor. This open-label phase I dose-escalation study (ClinicalTrials.gov Identifier: NCT00516451) aimed to assess the safety, preliminary efficacy, pharmacokinetics, and pharmacodynamics o...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3456941/ https://ncbi.nlm.nih.gov/pubmed/22878519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1932-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|